PDCD1 and melanoma: On the basis of the time-dependent ROC curve analysis, the optimal cutoff value that could be used for the 15 lncRNAs signature to stratify melanoma patients treated with anti-PD-1 monotherapy into the high- or low-risk group was determined to be 0.39 in the training cohort (Figure 4A–C).